Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhone-X open-label extension study of faricimab for diabetic macular edema
MOH_2020-12-30_009599Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of faricimab in diabetic macular edema (DME), sponsored by Roche. Primary endpoint: Long-term safety and tolerability. Started Dec 2020; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on MOH_2020-12-30_009599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-30_009599.